Since 1976, Tufts CSDD has provided robust, objective evidence-based research, analysis, and insight, which have informed stakeholders throughout the drug development enterprise. Here are select Tufts CSDD research milestones during our 46+ year history:

cost to develop new drug
patent life therapeutic compounds
orphan drug act
drug safety withdrawals
fda post-approval research
new drug cost study
biotechnology product discovery international
biotechnology success rates
FDA sponsor meetings new drug
PDUFA drug development times
FDAMA pediatric research incentive program
new drug biopharmaceutical approval times centralized procedure european medicines evaluation agency
cost pharmaceutical r&d develop new drug
FDA fast track program development times
follow-on drug development incremental innovation
drug safety withdrawals speed regulatory approval lack of correlation
cost develop new biotechnology product
outsourcing practice individual outsourcing models
oncology drug R&D approval success rate 8%
US drug plans 88% therapeutic non-compliant medicare regulations
new drug clinical success rates clinical success rates 16%
orphan drug development 25% new approvals
clinical useful diagnostics personalized medicines incidence protocol
protocol complexity
vaccine development trends
average cost pharmaceutical R&D
rapid growth pharmaceutical benefit managers exclusion lists drug developers
FDA 505 (b) (2) regulatory pathway review+process+molecular entity approvals
data volume data diversity clinical trials
patient engagement oncology development programs
real world evidence data artificial intelligence
volume cost vendor qualification re-qualification
participant demographic diversityp ivotal+trials+FDA+approved+drugs+biologics
Conducts first empirical study on the diversity of global site personnel and finds a strong positive correlation between the race and ethnicity of study staff and patients enrolled
Derives first cycle time benchmarks on the stages of adopting innovations supporting clinical operations